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Chloroquine (CQ)-resistant Plasmodium vivax was ﬁrst documented in 1989 and threatens much of east-
ern Indonesia, with > 50% of therapeutic failure rates. We screened 2236 subjects for malaria infection
through active case detection and identiﬁed 232 infected cases with 100 subjects carried P. vivax mono
infection. We prospectively evaluated therapeutic responses to CQ in 73 subjects infected by P. vivax in
northeastern Papua, Indonesia. We phenotyped these infections as susceptible or resistant to CQ using a
28-day in vivo test format. Eighteen subjects (25%) had persistent or recurrent parasitemia during the test
and were provisionally classiﬁed as resistant. Among the remainder, 46 (63%) subjects had no persistent
or recurrent parasitemia and were classiﬁed as having infections sensitive to CQ, 4 were lost to follow up,
and 5 dropped out. Among the 18 provisionally resistant cases, 1 subject (6%) had persistent parasitemia
at Day 3 and was considered as a direct treatment failure, 2 subjects (11%) had recurrent parasitemia by
Day 7 and were considered early treatment failures, and 7 (39%) and 8 (44%) had recurrent parasitemia by
Days 14 and 28, respectively. Analysis of blood for CQ+N-desethylchloroquine (DCQ) levels on day of
recurrence from 15 of the 18 with treatment failures showed 11 subjects having CQ+DCQ blood lev-
elsP 100 ng/ml and 2 with CQ+DCQ blood levels < 100 ng/ml. The 28-day cumulative incidence of ther-
apeutic failure likely due to parasite resistance was 17.5%. These ﬁndings afﬁrm P. vivax resistance to CQ
in eastern Indonesia, albeit at lower levels than reported elsewhere. This simple means of phenotyping P.
vivax infections could be implemented in other malaria endemic areas of Indonesia.
 2011Australian Society for Parasitology Inc. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Plasmodium vivax threatens 2.8 billion people with a debilitat-
ing and potentially lethal infection (Guerra et al., 2010). Chloro-
quine (CQ) remains ﬁrst-line therapy for acute vivax malaria
after 65 years despite more than 20 years of mounting evidence
of resistance (Baird, 2004, 2009). Resistance of Plasmodium falcipa-
rum to CQ appeared in the late 1950s in Southeast Asia and South
America (Wellems and Plowe, 2001), and today it occurs globallyInc. Published by Elsevier Ltd.
for Molecular Biology, Jalan
21 3917131; fax: +62 21
.
Op(Price and Nosten, 2001). Resistance of P. vivax to CQ was ﬁrst re-
ported in 1989 from an Australian repatriated from Papua New
Guinea (Rieckman et al., 1989). Resistance was subsequently re-
ported from Sumatra and Papua, Indonesia in 1991 (Baird et al.,
1991; Schwartz et al., 1991; Murphy et al., 1993), Myanmar in
1993 and 1995 (Myat-Phone et al., 1993; Than et al., 1995), India
in 1995 (Garg et al., 1995; Singh, 2000), Malaysian Borneo in
1996 (Clas et al., 1996), Guyana, South America in 1996 (Phillips
et al., 1996), parts of the Amazon Brazil (Alecrim et al., 1999; de
Santana et al., 2007; Simoes et al., 2007), Colombia in 2001 (Soto
et al., 2001), Vietnam in 2002 (Tasanor et al., 2002), Peru in 2003
(Ruebush et al., 2003), Turkey in 2004 (Kurcer et al., 2004), Ethiopia
in 2008 (Teka et al., 2008), and Republic of Korea in 2009 (Lee et al.,
2009). A 2003 report from northeastern Indonesian Papua showeden access under CC BY-NC-ND license.
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nata et al., 2003). More recent reports from eastern Indonesia show
failure rates routinely exceeding 50% (Tjitra et al., 2008). Chloro-
quine-resistant P. vivax (CRPV) represents a widespread and appar-
ently worsening problem.
Despite the importance of CRPV to public health, no standard-
ized means of ascertaining resistance has been developed. An
in vivo test procedure was described over a decade ago (WHO,
2000) and has been applied, at least partially, in some studies of
this problem. Unlike P. falciparum, some sporozoites of P. vivax stay
dormant in the liver as forms called hypnozoites, while others ini-
tiate the primary parasitemia and the consequent acute attack of
vivax malaria. Hypnozoites later activate, develop and cause a sec-
ondary parasitemia and acute disease called a relapse. In endemic
settings it is not known if any given patient presenting with acute
vivax malaria is experiencing a primary or secondary parasitemia.
This represents the fundamental problem for estimating therapeu-
tic efﬁcacy (Imwong et al., 2007): uncertainty regarding the origin
of the new parasitemia as a consequence of therapeutic failure as
opposed to relapse unrelated to treatment of the primary attack.
The in vivo test format (WHO, 2000) showed promise in solving
this ambiguity in the speciﬁc instance of CQ by avoiding the neces-
sity of appropriate classiﬁcation of recurrent parasitemia as re-
lapse, reinfection or recrudescence. It was reasoned that
parasitemia despite CQ levels exceeding the minimally effective
concentration (MEC) for CQ-sensitive P. vivax must be resistant
to CQ regardless of its origin (Baird et al., 1996, 1997). However,
such potential classiﬁcation bias remains, especially for studies
correlating CRPV phenotype and P. vivax genotype(s). The aim of
the current study was to establish a means of phenotyping CQ
resistance among parasites using an in vivo test format.2. Materials and methods
2.1. Study site
The study was conducted at Sentani (latitude 2340000S, longi-
tude 140290000E) northeastern Papua, Indonesia, from June to
August 2007. The area is typically meso- to hyper-endemic with
perennial falciparum and vivax malarias. The Anopheles punctulatus
group of mosquitoes are the overwhelmingly dominant vector spe-
cies (An. punctulatus, Anopheles farauti, and Anopheles koliensis) in
this region.
2.2. Subject enrolment
Cross-sectional microscopic surveys of blood ﬁlms from partic-
ipating subjects in endemic communities identiﬁed persons with P.
vivax asexual parasitemia. Potential study participants were ex-
cluded from study if found to be: (1) also positive for falciparum
or any other species of malaria; (2) positive for signs of severe or
complicated malaria; (3) pregnant; (4) positive for history of al-
lergy to the study drugs; (5) admitting to completion of antimalar-
ial therapy within past 72 h; or (6) having a medical history of
untreated hypertension or chronic heart, kidney or liver disease.
All adult subjects and the parents of child participants individually
signed informed consent to participate. The study protocol was re-
viewed and approved by the Eijkman Institute Research Ethics
Commitee for the use of human subjects in medical research.
2.3. Treatment
All study subjects were given directly observed treatment con-
sisting of a total dose of 25 mg/kg body weight of CQ over 48 h
(10 mg/kg on D0 and D1, and 5 mg/kg on D2). Subjects vomitingwithin 30 min were given another dose. Paracetamol was provided
to subjects with an axillary temperature ofP 37.5 C. Primaquine
therapy against relapse was not provided until discontinuation
from the study, i.e., day of recurrence or day 28.
2.4. Follow up
Study subjects were followed for up to 28 days. Subjects were
evaluated on Days 1, 2, 3, 7, 14, 21 and 28, or at any time they com-
plained of illness. Evaluation consisted of an axillary temperature
along with a blood sample collected by ﬁnger prick for both micro-
scopic and molecular examination (using ﬁlter paper; Whatman,
Schleicher & Schuell, Whatman International Ltd., Maidstone,
UK). Subjects not clearing parasitemia or developing recurrent par-
asitemia were offered unsupervised oral artemisinin combined
therapy (ACT; artesunate with amodiaquine) for 3 days plus pri-
maquine for 14 days (0.25 mg/kg/day) and were not further evalu-
ated. Subjects were discharged from the study upon treatment
failure, loss to follow-up, or reaching Day 28 without recurrent
parasitemia.
2.5. Treatment outcome classiﬁcation
Parasites infecting study subjects of the 28-day test were phe-
notyped for clinical responsiveness to CQ as follows.
(i) Sensitive: Asexual parasitemia not detectable by qualiﬁed
microscopy within 72 h of initiating therapy and failing to
recur up to day 28 after therapy.
(ii) Resistant: Asexual parasitemia remains detectable by quali-
ﬁed microscopy at 72 h after initiating therapy, or becoming
sub-patent but reappearing within 28 days of treatment in
the presence of blood levels of CQ+DCQ > 100 ng/ml, the
estimated minimally effective concentration (MEC) of CQ-
sensitive P. vivax (Patchen et al., 1983; Baird et al., 1996,
1997).
Resistant infections were further classiﬁed as direct treat-
ment failures if the microscopically patent asexual parasite-
mia on Day 2 was similar to or higher than that of Day 0
(P25%). Resistant infections were classiﬁed as early treat-
ment failures if they showed any level of microscopically
patent asexual parasitemia between Days 3–7. Subjects with
asexual parasitemia that became undetectable but reap-
peared at any time between Days 8 and 28 were provision-
ally classiﬁed as having recurrent treatment failures.
(iii) Indeterminate: Infections were classiﬁed as indeterminate
CQ resistance phenotypes when the study subject was with-
drawn from analysis for any reason, including loss to follow-
up, protocol violations, inter-current parasitemia by other
plasmodia, or recurrent P. vivax parasitemia with < 100 ng/
ml CQ+DCQ.
2.6. Whole blood CQ+DCQ levels
Blood levels of CQ and its major metabolite DCQ were measured
using high-performance liquid chromatography (HPLC) according
to the method previously described (Patchen et al., 1983). A micro-
pipette set to deliver 100 ll whole blood was used to spot this
blood onto ﬁlter paper on day of enrollment and at the time of
recurrence of parasitemia. Blood spots were air dried, placed in
ziplock bags and stored at ambient temperature until later testing.
Prior to extraction, an isopropyl analog of CQ was added to the
blood blot in a volume 50 ll and allowed to dry, to allow for an
extraction control. Following mincing of the ﬁlter paper, extraction
was performed using 0.5 ml of 20% Na3PO412H2O and 0.5 ml
methyl-tertbutylether. The solution was vortexed for 30 s and
Table 1
Characteristics of the subjects at enrollment in the 28 days in vivo CQ test in Jayapura
District.
Number of subjects 73
Median (range) age (year) 13.2 (2–60)
Median (range) hemoglobin level (D0) (g/dl) 11.8 (7–15)
Geometric mean asexual parasitemia per ll blood 560 (40–2080)
Mean CQ+DCQ level (ng/ml of blood) 40 (0–252)
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then transferred to another tube and evaporated to dryness with
air. The sample was reconstituted with HPLC mobile phase and a
portion was injected into the HPLC system (Waters™, USA).
2.7. Laboratory analysis
A ﬁnger prick was performed at enrolment to make thick and
thin blood smears, blots on ﬁlter paper for parasite genotyping,
and hemoglobin measurement (Hemocue™ Hb201+, Angelholm,
Sweden). Smears and ﬁlter paper blood samples were also col-
lected from ﬁnger pricks on days 1, 2, 3, 7, 14, 21 and 28. Smears
were read by expert microscopists and conﬁrmed by polymerase
chain reaction (PCR) (25). Parasite density was determined by
counting the number of parasites per leukocytes and assuming
an average of 8000 leukocytes/ll of blood to convert to volume
units (Gilles, 1993). Discordant ﬁndings between microscopy and
PCR were resolved by independent PCR conﬁrmation.3. Results
3.1. Recruitment
Of 2236 subjects screened, 340 (15%) were found positive for
malaria. Falciparum malaria dominated at 60% (206/340), followed
by vivax malaria at 32% (108/340). An additional 8 subjects (2%)
were positive for Plasmodium malariae, 16 (5%) had P. falciparum
and P. vivax co-infection, and 2 had P. vivax and P. malariae co-
infection. A total of 73 (68%) of the 108 P. vivax cases met inclusion
criteria. The 35 remaining subjects were excluded due to age, inad-
equate asexual parasitemia, or refusal of informed consent (Fig. 1).
During follow up, 4 subjects were lost from the study and 5
dropped out between Days 7–14 without citing reasons.
3.2. Subjects
Table 1 lists the demographic characteristics of the study sub-
jects at enrolment. Of 73 enrolled subjects, 36 were males and
37 were females, with ages ranging from 2 to 60 years (meanFig. 1. Flow chart of subject enrollment. ACPR = Adequate clinical and parasitological res
failure. ACPR = Adequate clinical and parasitological response; LTFU = Lost to-follow-up;38 years). At enrolment only 3 subjects had evidence of fever
(P37.5 C). Hemoglobin levels ranged from 7.3 to 15.3 g/dl and
24 subjects (33%) had Hb levels < 11 g/dl. The density of asexual
forms ranged from 40 to 2080/ll, whereas sexual stages (gameto-
cytes) occurred in 8 subjects (40–320/ll).
3.3. Parasite clearance
46 subjects cleared parasitemia before Day 3 and without again
becoming microscopically patent for vivax malaria up to Day 28
after enrollment. 18 other subjects had persistent or recurrent par-
asitemia during the test: 1 (6%) had persistent parasitemia at Day
3; another 2 (11%) cleared parasitemia before Day 3 but recurred
by Day 7; by day 14 another 7 subjects (39%) had recurrent para-
sitemia, as did 8 others (44%) by Day 28. The balance of 9 subjects
of the 73 enrolled were either lost (4) or dropped out (5). The 28-
day cumulative incidence of therapeutic failure was 17% (Table 2).
3.4. Adverse reactions
The most frequent clinical complaints reported by subjects at
the time of enrolment were headache (24%), fever (20%), rigors
(11%), dizziness (11%), weakness (2%), nausea (2%) and vomiting
(1%). No severe side effects were noted in any of the subjects en-
rolled and all recovered uneventfully within 3 days of treatment.
3.5. CQ+DCQ blood levels
A total of 24 subjects (33%) had detectable CQ in blood before
treatment, with concentrations ranging from 19 to 90 ng/ml andponse; LTFU = Lost to-follow-up; ETF = Early treatment failure; LTF = Late treatment
ETF = Early treatment failure; LTF = Late treatment failure.
Table 2
Cumulative incidence of CQ therapeutic failure in vivax malaria at Sentani, northeastern Papua, Indonesia.
Day Number at risk (N) Incident cases (I) Withdrawn (W) Interval risk (IR) Cumulative risk (CR)
0 73 0 0 0 0
3 73 1 3 0.0143 0.0143
5 69 1 1 0.0147 0.0288
7 67 1 0 0.0149 0.0433
11 66 0 2 0 0.0433
13 64 0 1 0 0.0433
14 63 4 4 0.0678 0.1081
15 55 2 0 0.0364 0.1406
17 53 1 0 0.0189 0.1568
18 52 0 1 0 0.1568
20 51 0 1 0 0.1568
21 50 1 3 0.0213 0.1747
28 46 0 0 0 0.1747
Day = day of the test.
N = number of subjects remaining at risk.
I = incident of resistant cases.
W = withdrawals due to intercurrent parasitemia by the other species, drop out and CQ level less than 100 ng/ml at positive malaria.
IR = interval risk i{N  (w/2)}1.
CIRn = cumulative incidence of resistant case.
=1  ((1  IRn)  (1  CIFn1)) where n is day of test and n  1 is the prior interval, e.g., for calculating CIR day 14, use IR day 14 and CIR day 7.
Table 3
HPLC analysis of the CQ plus DCQ blood level on recurrent days among the subjects
with treatment failure.
Subject’s code Drug level (ng/ml of blood) Phenotype*
D0 DR
CRPV-005 38 454 Resistant
CRPV-007 ND 231 Resistant
CRPV-008 ND 181 Resistant
CRPV-011 41 439 Resistant
CRPV-012 ND 423 Resistant
CRPV-013 97 204 Resistant
CRPV-014 56 516 Resistant
CRPV-030 16 238 Resistant
CRPV-033 ND ND NA
CRPV-036 22 409 Resistant
CRPV-041 ND 147 Resistant
CRPV-042 164 ND NA
CRPV-045 ND 43 NA
CRPV-046 252 100 Resistant
CRPV-061 31 ND NA
CRPV-062 106 ND NA
CRPV-063 96 24 NA
CRPV-064 ND ND NA
D0 = day of enrollment; DR = day of recurrence; ND = not determined; NA = not
applicable.
* MEC: minimum effective concentration = 100 ng/ml.
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undetectable CQ at the day before treatment. Table 3 summarizes
the analysis of CQ+DCQ levels among the 18 subjects with recur-
rent parasitemia. Samples from 5 subjects were unavailable.
Among the remaining 13, CQ+DCQ blood levels wereP 100 ng/
ml in 11 and < 100 ng/ml in 2.4. Discussion
This study applied a relatively simple algorithm to classify
P. vivax infection as clinically resistant or sensitive to CQ. Minimiz-
ing the probability of misclassiﬁcation requires completion of the
28-day in vivo test, along with ensuring directly observed therapy
and addressing other potential confounders of therapeutic out-
come like poor drug absorbtion (Sumawinata et al., 2003). The
amount of drug on day of recurrent parasitemia represents a crit-
ical tool in phenotyping CQ resistance; the measurement avoids
confounding due to uncertainty regarding the possible causes ofrecurrence: recrudescence, reinfection, or relapse (Baird et al.,
1997).
Parasites in subjects clearing asexual parasitemia within 3 days
who had no recurrent asexual parasitemia up to day 28 were phe-
notyped, a priori, as sensitive to CQ. Likewise, parasites in subjects
failing to clear microscopically patent asexual parasitemia within
3 days or reappearing within 7 days were phenotyped, a priori,
resistant to CQ. However, infections that reappeared between days
8 and 28 were only provisionally classiﬁed as resistant. These
infections required measurement of CQ+DCQ in whole blood on
the day of recurrence: parasitemias recurring withP 100 ng/ml
CQ+DCQ were conﬁrmed as resistant, and those recurring
with < 100 ng/ml were classiﬁed as indeterminate.
Asexual parasitemia recurring in the 28 days following treat-
ment with CQ may originate from recrudescence, reinfection or re-
lapse. The algorithm for phenotyping clinical resistance to CQ we
applied in this study does not attempt to distinguish these sources
of parasitemia. Instead, we classiﬁed recurrences appearing
withP 100 ng/ml CQ+DCQ as unambiguously resistant on the
weight of evidence provided by development to microscopic pa-
tency despite drug levels known to be lethal to CQ sensitive P.
vivax.
Among the 73 subjects evaluated at the study site in Sentani,
Papua, Indonesia, 13 parasitemias were classiﬁed as indeterminate,
49 as sensitive, and 11 as resistant. Because the indeterminate
infections contribute person-time at risk of treatment failure prior
to withdrawal, a life table analysis provides the ideal means of esti-
mating overall risk of therapeutic failure in the study population.
In this study, that method provided the estimate of 17% as the
28-day cumulative incidence of resistance at the study site in
2007. This is much lower risk than an estimate of 84% derived from
non-immune migrants to the nearby Arso region (Sumawinata
et al., 2003). Naturally acquired immunity conferred by repeated
infection among life-long indigenous residents of Sentani may lar-
gely explain the sharp difference in these estimates.
This study generated 49 populations of parasites conﬁrmed to
be clinically sensitive to CQ, and 11 others conﬁrmed as clinically
resistant. The parasite populations classiﬁed as sensitive were rep-
resented by those present at enrollment. The same may be said of
the parasite populations classiﬁed as direct or early treatment fail-
ures. However, among recurrent treatment failures, the parasite
populations present at enrollment cannot be phenotyped – it is
only the parasite populations appearing on the day of recurrence
that represent that phenotype.
32 P.B.S. Asih et al. / International Journal for Parasitology: Drugs and Drug Resistance 1 (2011) 28–32In conclusion, this study successfully phenotyped 11 CQ-resis-
tant P. vivax isolates in Papua Indonesia and this might be a vital
step in studies leading to identiﬁcation of the underlying genetic
polymorphisms. Further study to determine the extent of CQ resis-
tance in this and other populations at risk, especially given the high
frequency of P. vivax infection and its newly appreciated potential
to cause severe outcomes, is required.Acknowledgments
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